Comparative Pharmacology
Head-to-head clinical analysis: PANCURONIUM BROMIDE versus TRACRIUM PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PANCURONIUM BROMIDE versus TRACRIUM PRESERVATIVE FREE.
PANCURONIUM BROMIDE vs TRACRIUM PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine from binding and thus inhibiting muscle contraction.
Competitive antagonist of nicotinic acetylcholine receptors at the neuromuscular junction, blocking depolarization and preventing muscle contraction.
0.04-0.1 mg/kg IV initial bolus, then 0.01-0.02 mg/kg IV every 20-40 min as needed for neuromuscular blockade.
Initial dose 0.4-0.5 mg/kg IV bolus for intubation; maintenance 0.08-0.1 mg/kg IV every 20-45 minutes as needed or continuous infusion 5-10 mcg/kg/min
None Documented
None Documented
Terminal elimination half-life: 100-120 minutes in adults with normal renal function; prolonged to 240-480 minutes in renal failure.
Terminal elimination half-life: 20-30 minutes (healthy adults). Clinically, recovery is rapid due to redistribution and Hofmann elimination; prolonged in hypothermia or acidosis.
Renal: 50-70% unchanged; biliary/fecal: 5-10% as metabolites; minor hepatic metabolism.
Renal: 10-20% unchanged; biliary/fecal: 50-60% as metabolites and parent drug; Hofmann elimination (non-enzymatic) accounts for ~45% of clearance.
Category C
Category C
Neuromuscular Blocking Agent
Neuromuscular Blocking Agent